BioMed Research International

Research Article

The Oncofetal Protein IMP3: A Novel Grading Tool and Predictor of Poor Clinical Outcome in Human Gliomas

Table 3

The Oncomine repository¹ was queried for IMP3 (IGF2BP3) differential expression in brain cancers and only studies performed on human tissues were considered. The name of the study, the samples for which the comparison was significant², the relative expression difference (fold change), and the associated value ( statistic provided within the database) are reported.


Study	Comparison³	Analysis⁴	P value	Fold change

TGCA brain	OD versus normal brain	GEX		7.03

Nutt brain	GBM versus OD	GEX		3.2

Sun brain	OD versus normal brain	GEX		9.07
	OD versus normal brain			4.04
	AA versus normal brain			3.2

Murat brain	OD versus normal brain	GEX		3.67

Liang brain	GBM versus OD and mixed glioma	GEX		2.2

Bredel brain 2	GBM versus brain cancers	GEX		2.05
Bredel brain 2	OD versus normal brain	GEX		4

Shai brain	GBM versus brain cancers	GEX		1.71
Shai brain	OD versus normal brain	GEX		1.78

TGCA brain 2	GBM versus brain cancers	CNV		1.2
	OD versus normal brain			1.1
	OD versus normal brain			1.3

Beroukhim brain	OD versus normal brain	CNV		1.14
Beroukhim brain	GBM versus brain cancers	CNV		1.08

https://www.oncomine.org/resource/login.html.
value less than .
³GBM: glioblastoma; OD: oligodendroglioma.
⁴GEX: gene expression analysis; CNV: DNA copy number variation analysis.